Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Generic Pharmaceutical Association (GPhA)

Generic Pharmaceutical Association Changes Name to Association for Accessible Medicines; Launches Education Campaign

Washington, DC, February 22, 2017 — The Generic Pharmaceutical Association (GPhA), the nation’s largest trade group representing generic pharmaceutical and biosimilar companies, on February 14 week unveiled a new national effort to contain the cost of prescription medicines.

The group is becoming the Association for Accessible Medicines (AAM) to communicate its mission to make more medicines more accessible to more people who need them. Continue reading

Report: Generic Drug Savings Reached $227 Billion in 2015

gpha-twitterWashington, DC, October 20, 2016 — Annual savings from generic prescription drugs increased 328 percent from 2005-2016, according to the new 2016 Generic Drug Savings and Access in the United States report, compiled by the QuintilesIMS Institute on behalf of the Generic Pharmaceutical Association (GPhA).

This report confirms again that generic drugs are essential to reducing health costs and play a critical role in growing patient access.

“Generic drugs are the foundation of any successful effort to lower health spending and increase patient access to affordable medicine,” said Chip Davis, President and CEO, GPhA. Continue reading

Kaiser Health News: EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog

Generic 1Washington, DC, September 6, 2016 — Sydney Lupkin reports on Kaiser Health News website that consumers and Congress members pushing for cheaper alternatives to the EpiPen and other high-priced drugs are seeking answers about a stubborn backlog of generic drug applications at the Food and Drug Administration that still stretches almost four years.

As of July 1, the FDA had 4,036 generic drug applications awaiting approval, and the median time it takes for the FDA to approve a generic is now 47 months, according to the Generic Pharmaceutical Association (GPhA).

The FDA has approved more generics the past few years, but a flood of new applications has steadily added to the demand. Continue reading

Report: Generic Drugs Deliver a $254 Billion in Savings to U.S. Health Care System in 2014

Generic 1Washington, DC, December 14, 2015 ― The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

For the first time, this year’s report includes state-by-state savings from generics.

It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers. Continue reading

GPhA Report: Generic Drugs Deliver a $254 Billion in Savings to 2014 U.S. Health Care System

Generic 1Washington, DC, December 5, 2015 ― The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

For the first time, this year’s report, released in November, includes state-by-state savings from generics.

It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers. Continue reading

New Report Shows Generic Drugs Deliver a $254 Billion in Savings to U.S. Health Care System in 2014

Generic 1Washington, DC, November 4, 2015 ― The U.S. health care system saved a record $254 billion in 2014 from generic drugs, which amounts to $1.68 trillion over the most recent decade (2005-2014), according to the seventh annual Generic Drug Savings in the United States report compiled by the IMS Institute for Healthcare Informatics on behalf of the Generic Pharmaceutical Association (GPhA).

For the first time, this year’s report includes state-by-state savings from generics.

It also details the key role generic drugs play in Medicare and Medicaid savings, resulting in billions of dollars of savings to federal and state budgets, beneficiaries and taxpayers. Continue reading

Generic Pharmaceutical Association Names Chester ‘Chip’ Davis as President and CEO

Chip Davis

Chip Davis

Washington, DC, July 23, 2015 ― The Generic Pharmaceutical Association (GPhA) yesterday announced it had named Chester “Chip” Davis, Jr. President and CEO.  Davis, who will assume the role effective August 18, succeeds CEO Ralph Neas.

Davis currently is the Executive Vice President for Advocacy and Member Relations at PhRMA.  He leads PhRMA’s federal, state and international government relations and advocacy efforts, and is also responsible for membership recruitment and retention. Continue reading

Biopharma Trade Groups Ask US Supreme Court to Review California County Drug Take-Back Program

New York, NY, January 7, 2015 ― Pharmalot reports that, angry over a drug take-back program instituted by a California county, the pharmaceutical industry has asked the US Supreme Court to review the constitutionality of the program.

In a filing on December 29, three trade groups — the Pharmaceutical Research and Manufacturers of America (PhRMA), the Generic Pharmaceuticals Association (GPhA) and the Biotechnology Industry Organization (BIO) — argue that a federal appeals court erred last September when it upheld a lower-court ruling that the program did not violate the Constitution.

The trade groups maintain that Alameda County interfered with interstate commerce and discriminates against out-of-state drug makers. Continue reading